Cartesian Therapeutics is a clinical-stage biotechnology company developing novel cellular immunotherapies to cure cancer. Cartesian’s proprietary technology, originally developed by NIH researchers, has the potential to greatly broaden the use of Chimeric Antigen Receptor (CAR) cells for patients with multiple myeloma and other diseases.